Abstract

Nicotinamide adenine dinucleotide (NAD+) extends longevity in experimental organisms, raising interest in its impact on human health. De novo NAD+ biosynthesis from tryptophan is evolutionarily conserved yet considered supplanted among higher species by biosynthesis from nicotinamide (NAM). Here we show that a bottleneck enzyme in de novo biosynthesis, quinolinate phosphoribosyltransferase (QPRT), defends renal NAD+ and mediates resistance to acute kidney injury (AKI). Following murine AKI, renal NAD+ fell, quinolinate rose, and QPRT declined. QPRT+/− mice exhibited higher quinolinate, lower NAD+, and higher AKI susceptibility. Metabolomics suggested an elevated urinary quinolinate/tryptophan ratio (uQ/T) as an indicator of reduced QPRT. Elevated uQ/T predicted AKI and other adverse outcomes in critically ill patients. A phase 1 placebo-controlled study of oral NAM demonstrated a dose-related increase in circulating NAD+ metabolites. NAM was well tolerated and was associated with less AKI. Therefore, impaired NAD+ biosynthesis may be a feature of high-risk hospitalizations for which NAD+ augmentation could be beneficial.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Bonkowski, M. S. & Sinclair, D. A. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat. Rev. Mol. Cell Biol. 17, 679–690 (2016).

  2. 2.

    Cantó, C., Menzies, K. J. & Auwerx, J. NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 22, 31–53 (2015).

  3. 3.

    Ternes, C. M. & Schönknecht, G. Gene transfers shaped the evolution of de novo NAD+ biosynthesis in eukaryotes. Genome Biol. Evol. 6, 2335–2349 (2014).

  4. 4.

    Collins, P. B. & Chaykin, S. The management of nicotinamide and nicotinic acid in the mouse. J. Biol. Chem. 247, 778–783 (1972).

  5. 5.

    Krehl, W. A., Teply, L. J., Sarma, P. S. & Elvehjem, C. A. Growth-retarding effect of corn in nicotinic acid-low rations and its counteraction by tryptophane. Science 101, 489–490 (1945).

  6. 6.

    Kleta, R. et al. Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat. Genet. 36, 999–1002 (2004).

  7. 7.

    Cantó, C. et al. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15, 838–847 (2012).

  8. 8.

    Wang, G. et al. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 158, 1324–1334 (2014).

  9. 9.

    Williams, P. A. et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science 355, 756–760 (2017).

  10. 10.

    Anderson, R. M., Bitterman, K. J., Wood, J. G., Medvedik, O. & Sinclair, D. A. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature 423, 181–185 (2003).

  11. 11.

    Gomes, A. P. et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155, 1624–1638 (2013).

  12. 12.

    Zhang, H. et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science 352, 1436–1443 (2016).

  13. 13.

    Lin, S. J., Defossez, P. A. & Guarente, L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289, 2126–2128 (2000).

  14. 14.

    Verdin, E. NAD+ in aging, metabolism, and neurodegeneration. Science 350, 1208–1213 (2015).

  15. 15.

    Mills, K. F. et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 24, 795–806 (2016).

  16. 16.

    Mehta, R. L. et al. International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet 385, 2616–2643 (2015).

  17. 17.

    Tran, M. T. et al. PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature 531, 528–532 (2016).

  18. 18.

    Lewington, A. J., Cerdá, J. & Mehta, R. L. Raising awareness of acute kidney injury: a global perspective of a silent killer. Kidney Int. 84, 457–467 (2013).

  19. 19.

    Leaf, D. E. et al. Fibroblast growth factor 23 levels associate with AKI and death in critical illness. J. Am. Soc. Nephrol. 28, 1877–1885 (2017).

  20. 20.

    Gale, E. A. et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363, 925–931 (2004).

  21. 21.

    Chen, A. C. et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N. Engl. J. Med. 373, 1618–1626 (2015).

  22. 22.

    Trammell, S. A. et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat. Commun. 7, 12948 (2016).

  23. 23.

    Petley, A., Macklin, B., Renwick, A. G. & Wilkin, T. J. The pharmacokinetics of nicotinamide in humans and rodents. Diabetes 44, 152–155 (1995).

  24. 24.

    Bai, P. et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 13, 461–468 (2011).

  25. 25.

    Morigi, M. et al. Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. J. Clin. Invest. 125, 715–726 (2015).

  26. 26.

    Agledal, L., Niere, M. & Ziegler, M. The phosphate makes a difference: cellular functions of NADP. Redox Rep. 15, 2–10 (2010).

  27. 27.

    Kirkland, J. B. Niacin requirements for genomic stability. Mutat. Res. 733, 14–20 (2012).

  28. 28.

    Shi, H. et al. NAD deficiency, congenital malformations, and niacin supplementation. N. Engl. J. Med. 377, 544–552 (2017).

  29. 29.

    Wang, Y. et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat. Med. 16, 279–285 (2010).

  30. 30.

    Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197–203 (2011).

  31. 31.

    Christen, S., Peterhans, E. & Stocker, R. Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases. Proc. Natl Acad. Sci. USA 87, 2506–2510 (1990).

  32. 32.

    Cervenka, I., Agudelo, L. Z. & Ruas, J. L. Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health. Science 357, eaaf9794 (2017).

  33. 33.

    Underwood, E. The final countdown. Science 350, 1188–1190 (2015).

  34. 34.

    Hausenloy, D. J. et al. Remote ischemic preconditioning and outcomes of cardiac surgery. N. Engl. J. Med. 373, 1408–1417 (2015).

  35. 35.

    Garg, A. X. et al. Kidney function after off-pump or on-pump coronary artery bypass graft surgery: a randomized clinical trial. JAMA 311, 2191–2198 (2014).

  36. 36.

    Ebrahimkhani, M. R. et al. Aag-initiated base excision repair promotes ischemia reperfusion injury in liver, brain, and kidney. Proc. Natl Acad. Sci. USA 111, E4878–4886 (2014).

  37. 37.

    Langholz, B. & Goldstein, L. Risk set sampling in epidemiologic cohort studies. Stat. Sci. 11, 35–53 (1996).

  38. 38.

    Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl. 2, 1–138 (2012).

  39. 39.

    Knaus, W. A., Draper, E. A., Wagner, D. P. & Zimmerman, J. E. APACHE II: a severity of disease classification system. Crit. Care Med. 13, 818–829 (1985).

  40. 40.

    Harris, P. A. et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377–381 (2009).

Download references

Acknowledgements

This randomized clinical trial was funded by an Innovation Grant from the BIDMC awarded to A.P.M. and K.R.K. K.M.R., V.W., A.K., and M.R.L. were supported by T32DK007199; D.E.L. by K23DK106448; C.C.K. and R.I.T. by T32DK007540; S.J.H. by K23AG042459; N.S.-T. by a grant from Assistance Publique—Hôpitaux de Paris; and A.H.B. by K08HL121801 and R56HL133399. Work in S.M.P.’s laboratory was supported by R35HL139424, R01HL125275, and R01DK095072.

Author information

Author notes

  1. These authors contributed equally: Ali Poyan Mehr, Mei T. Tran, Kenneth M. Ralto.

  2. These authors jointly supervised: Kamal R. Khabbaz, Anders H. Berg, Samir M. Parikh.

Affiliations

  1. Division of Nephrology and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

    • Ali Poyan Mehr
    • , Mei T. Tran
    • , Kenneth M. Ralto
    • , Vaughan Washco
    • , Joseph Messmer
    • , Ajay Kher
    • , Steven H. Kim
    • , Noemie Simon-Tillaux
    • , Matthew R. Lynch
    •  & Samir M. Parikh
  2. Division of Pulmonary and Critical Care and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

    • Kenneth M. Ralto
  3. Division of Pulmonary and Critical Care, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    • Kenneth M. Ralto
  4. Division of Renal Medicine and Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

    • David E. Leaf
    •  & Sushrut S. Waikar
  5. Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

    • Adam Lerner
  6. Division of Nephrology and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    • Charbel C. Khoury
    • , Ravi I. Thadhani
    •  & Eugene P. Rhee
  7. Division of General Medicine and Primary Care Medicine and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

    • Shoshana J. Herzig
  8. Cardiovascular Institute and Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

    • Mary E. Trovato
    •  & Kamal R. Khabbaz
  9. Broad Institute of Harvard and MIT, Cambridge, MA, USA

    • Clary B. Clish
    •  & Eugene P. Rhee
  10. Endocrine Unit and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    • Eugene P. Rhee
  11. Division of Clinical Chemistry and Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

    • Anders H. Berg

Authors

  1. Search for Ali Poyan Mehr in:

  2. Search for Mei T. Tran in:

  3. Search for Kenneth M. Ralto in:

  4. Search for David E. Leaf in:

  5. Search for Vaughan Washco in:

  6. Search for Joseph Messmer in:

  7. Search for Adam Lerner in:

  8. Search for Ajay Kher in:

  9. Search for Steven H. Kim in:

  10. Search for Charbel C. Khoury in:

  11. Search for Shoshana J. Herzig in:

  12. Search for Mary E. Trovato in:

  13. Search for Noemie Simon-Tillaux in:

  14. Search for Matthew R. Lynch in:

  15. Search for Ravi I. Thadhani in:

  16. Search for Clary B. Clish in:

  17. Search for Kamal R. Khabbaz in:

  18. Search for Eugene P. Rhee in:

  19. Search for Sushrut S. Waikar in:

  20. Search for Anders H. Berg in:

  21. Search for Samir M. Parikh in:

Contributions

A.P.M. and K.R.K. were co-principal investigators on the phase 1 pilot study of oral NAM in cardiac surgery patients for which V.W., J.M., A.L., and M.E.T. were coinvestigators. S.J.H. served as the independent medical monitor for this trial. K.M.R., N.S.-T., and A.H.B. analyzed samples and data from all human studies. A.H.B. developed targeted metabolic assays and conducted all related measurements. M.T.T. conducted the mouse studies and analyzed the results with assistance from N.S.-T. and M.R.L. D.E.L. and S.S.W. enrolled the ICU cohort, created that repository, and performed statistical analyses of the uQ/T results in the ICU cohort. A.K. and S.H.K. enrolled the discovery cohort of cardiac surgery patients and created that repository with guidance from S.M.P. C.C.K., E.P.R., and R.I.T. developed and conducted the trial of oral NAM in healthy volunteers. E.P.R. also conducted metabolomic screening of mouse samples on the platform developed in C.B.C.’s laboratory with input from C.B.C. A.P.M., M.T.T., K.M.R., and S.M.P. assumed primary responsibility for writing the manuscript. All authors reviewed, provided substantive input, and approved of the final manuscript.

Competing interests

S.M.P. is listed as an inventor on disclosures filed by BIDMC pertaining to NAD+.

Corresponding author

Correspondence to Samir M. Parikh.

Supplementary Information

  1. Supplementary Text and Figures

    Supplementary Figures 1–7 and Supplementary Tables 1–12

  2. Reporting Summary

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41591-018-0138-z